ClinVar Miner

Submissions for variant NM_003242.6(TGFBR2):c.902A>G (p.His301Arg) (rs863223857)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000200455 SCV000250964 uncertain significance not provided 2016-07-26 criteria provided, single submitter clinical testing The H301R variant in the TGFBR2 gene has been detected in three individuals reported to have Loeys- Dietz syndrome (Frischmeyer-Guerrerio et al., 2013); however, no segregation studies or clinical information was provided. The H301R variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. This substitution occurs at a position that is conserved across species, and in silico analysis predicts this variant is probably damaging to the protein structure/function. Moreover, a missense variant in a nearby residue (L308P) has been reported in association with a TGFBR2-related disorder (Stenson et al., 2014). Nevertheless, the H301R variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. Furthermore, to our knowledge, no studies have been performed to determine the functional effect of the H301R variant. Thus, this variant lacks observation in a significant number of affected individuals, segregation data, and functional evidence, which would further clarify its pathogenicity. Therefore, based on the currently available information, it is unclear whether this variant is pathogenic or benign.
Ambry Genetics RCV000251947 SCV000319183 uncertain significance Cardiovascular phenotype 2013-11-01 criteria provided, single submitter clinical testing The p.H301R variant (also known as c.902A>G), located in coding exon 4 of the TGFBR2 gene, results from an A to G substitution at nucleotide position 902. The histidine at codon 301 is replaced by arginine, an amino acid with highly similar properties, and is located in a serine/threonine protein kinase domain. This variant was detected in 3 individuals from a Loeys-Dietz syndrome cohort; however, clinical details were not provided (Frischmeyer-Guerrerio PA. Sci Transl Med. 2013 Jul;5(195):195ra94). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000590283 SCV000698199 likely pathogenic Loeys-Dietz syndrome 2019-02-28 criteria provided, single submitter clinical testing Variant summary: TGFBR2 c.902A>G (p.His301Arg) results in a non-conservative amino acid change located in the Serine-threonine/tyrosine-protein kinase, catalytic domain (IPR001245) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. This is supported by a study evaluating variants in TGFBR2 using genomics and structure based evaluations that classified this variant as "Pathogenic" (Zimmermann_2017). The variant was absent in 245738 control chromosomes. c.902A>G has been reported in the literature in 3 individuals affected with Loeys-Dietz Syndrome (Frischmeyer-Guerrerio 2013), and in 1 familial case tested in our laboratory, where the variant segregated with a strong family history of abdominal and aortic aneurysms/dissections. These data indicate that the variant is likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as likely pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.